Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain
María Lloret Avellá, Mafalda Carmo, Núria Paladio Duran, Pere Blancher Parcerisa · 2026
Read Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain by María Lloret Avellá, Mafalda Carmo, Núria Paladio Duran, Pere Blancher Parcerisa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0358426.txt.
Description
María Lloret Avellá and three colleagues count what it costs Spain's health system just to give leukemia drugs, in PLOS ONE in 2026. Older patients with acute myeloid leukemia who cannot face intensive chemotherapy receive a class of drugs by vein or under the skin, meaning repeated hospital trips. An oral version exists and works equivalently. The team priced everything except the drugs themselves, from preparation to transport, catheters, and infections, using a survey of thirty professionals at sixteen hospitals.
The non drug cost per patient came to roughly ten thousand euros for the intravenous route and over twelve thousand for the under skin route. The oral route cost barely thirteen hundred, a saving of nearly ninety percent. Fewer visits drive nearly all of the gap. The authors frame the switch as an organizational relief for crowded hospitals as much as a budget saving.
Catalog record
| CREATOR | María Lloret Avellá, Mafalda Carmo, Núria Paladio Duran, Pere Blancher Parcerisa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32472 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |